ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Review
Revised

SMARCB1/INI1-deficient tumors of adulthood

[version 2; peer review: 2 approved]
PUBLISHED 09 Dec 2020
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

The SMARCB1/INI1 gene was first discovered in the mid-1990s, and since then it has been revealed that loss of function mutations in this gene result in aggressive rhabdoid tumors. Recently, the term “rhabdoid tumor” has become synonymous with decreased SMARCB1/INI1 expression. When genetic aberrations in the SMARCB1/INI1 gene occur, the result can cause complete loss of expression, decreased expression, and mosaic expression. Although SMARCB1/INI1-deficient tumors are predominantly sarcomas, this is a diverse group of tumors with mixed phenotypes, which can often make the diagnosis challenging. Prognosis for these aggressive tumors is often poor. Moreover, refractory and relapsing progressive disease is common. As a result, accurate and timely diagnosis is imperative. Despite the SMARCB1/INI1 gene itself and its implications in tumorigenesis being discovered over two decades ago, there is a paucity of rhabdoid tumor cases reported in the literature that detail SMARCB1/INI1 expression. Much work remains if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors.

Keywords

SMARCB1, INI1, loss of function mutation, rhabdoid, sarcoma

Revised Amendments from Version 1

I thoroughly appreciated reviewing the comments of the Peer Reviewer. All suggestions have been addressed and the appropriate changes have been made, including minor grammatical changes and clarification of definitions. Thank you for the feedback.

To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.

History of the SMARCB1/INI1 Gene

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also known as integrase interactor 1 (INI1), is a crucial component of a chromatin-remodeling protein complex. SMARCB1/INI1 was first identified in yeast in the late 1980s1. By 1994, its human homologue was isolated in fibroblast cells2,3. Subsequent molecular investigations showed this nuclear protein complex enhances DNA transcription by interactions with HIV-1 integrase2. Nuclear SMARCB1/INI1 exists ubiquitously in all normal cells, and acts as a tumor suppressor gene4. It was revealed in the early 2000s by studies in mice that biallelic knockout of the SMARCB1/INI1 gene resulted in early lethality5. Mice with heterozygous loss before birth, or who had later conditional single-allele knockout after birth, of SMARCB1/INI1 developed aggressive rhabdoid tumors68. Since its discovery, much work has revealed this chromatin-remodeling protein has crucial roles in multiple signaling pathways that function to suppress tumorigenesis and tumor growth9. Although these pathways are highly complex, the development and use of targeted anti-cancer therapies has practically become ubiquitous for nearly all solid tumors. Thus, continued investigations are needed if we hope to provide additional therapeutic strategies for patients with aggressive SMARCB1/INI1-deficient tumors9.

Interestingly, the genetic signatures of SMARCB1/INI1-deficient tumors are far from monotonous. Three distinct patterns of abnormal SMARCB1/INI1 gene expression have been identified – reduced, complete loss, and mosaic9.

Epidemiology, clinical, prognosis

Complete loss of SMARCB1/INI1 expression has been linked to a number of pediatric and adult sarcomas (Table 1). Malignant rhabdoid tumor (MRT) and epithelioid sarcoma (ES) both result from biallelic deletions or mutations causing a complete loss of SMARCB1/INI1 expression41. Commonly arising before the age of three years old, MRTs are considered one of the most aggressive childhood neoplasms associated with high mortality41. MRTs have been reported in adults4249. Based on MRT of adulthood being primarily reported anecdotally, estimated rates of incidence remain unclear. Data concerning the 5-year survival rate for MRT in adults is difficult to determine as well, as various percentages have been reported in literature13,14. However, estimated average survival following MRT diagnosis has been reported to be six months10.

Table 1. Epidemiologic, selected clinical, and prognostic data for SMARCB1/INI1-deficient tumors.

STS, soft tissue sarcomas; MRT, malignant rhabdoid tumor; CNS, central nervous system; MPNST, malignant peripheral nerve sheath tumor; NF-1, neurofibromatosis type 1; NF-2; neurofibromatosis type 2, GI, gastrointestinal; NA, data not available.

Epidemiology, ClinicalSurvival
Reduced
expression
Synovial sarcoma5 – 10% of all STS; median age of 40 years; males10,115-year, 36–76%11
Complete lossMalignant rhabdoid tumorTypically < 3 years of age11; typically presents
intraabdominally in adult males10,12
MRT: 5-year, 15 – 20%13;
extrarenal rhabdoid
tumor: 5-year, 35%14
Atypical teratoid/rhabdoid
tumor
Typically < 3 years of age; 10% of CNS tumors in infants1220 months15,16
Epithelioid sarcoma< 1% of all STS; median age of 27 years, males175-year, 68% (all ages)18
Renal medullary carcinomaThird most common kidney cancer among children
and young adults; median age of 28 years; males19,20
Overall survival less than
12 months19
Epithelioid malignant
peripheral nerve sheath
tumor
< 1% of all STS; < 5% of all MPNSTs; aggressive MPNST
variant; unlike MPNST uncommonly associated with NF-1;
median age > 40 years21,22
5-year, 34 – 43%22
Myoepithelial carcinomaAbout 70% occur in parotid gland; median age of
55 years23
5-year, 71%24
Extraskeletal myxoid
chondrosarcoma
< 3% of all STS; median age of 50 years; males255-year, 80 – 90%25
ChordomaMedian age of 50 – 60 years in adults, males; median age of
10 – 12 years in children, females26,27
5-year, 70%28
Pancreas undifferentiated
rhabdoid carcinoma
Heterogeneous group of neoplasms; poorly characterized29NA
Sinonasal basaloid carcinoma< 5% of all head/neck cancers; 0.5 cases per 100,000
population per year; males30
Median overall survival
17 months31
Rhabdoid carcinoma of the
gastrointestinal tract
About 0.1% of all gastric cancers; < 50 cases reported in the
upper and lower GI tract32,33
Overall survival six
months33
Mosaic
expression
SchwannomatosisThird major form of neurofibromatosis; distinct from NF-1
and NF-2; median age of 40 years; 20% familial34
NA
Gastrointestinal stromal
tumor
5% of all STS, 80% of all mesenchymal GI tract tumors;
median age of 60 years3537
5-year, 83%38
Ossifying fibromyxoid
tumor
Only 300 cases reported worldwide; median age of 50 years;
males39,40
NA

ES is now categorized into two subgroups: distal and proximal. Conventional or distal-type ES tends to be histologically similar squamous cells. Also, distal-type ES immunohistochemical (IHC) profiles can be diverse. Proximal-type ES is thought to be the more aggressive variant, and has an affinity for the proximal limbs of young adults. Microscopically, sheets of large rhabdoid tumor cells are predominantly observed50. Based on more recent clinicopathologic and IHC data, many tumors that were previously diagnosed as a MRT are now classified as proximal ES51.

In addition to ES, atypical teratoid/rhabdoid tumor, renal medullary carcinoma, and pediatric chordoma are rare sarcomas that result from the complete loss of SMARCB1/INI1 expression (Table 1). They predominantly occur in pediatric or young adult patients. Collectively, these neoplasms typically develop in the head/neck, CNS, thorax, kidneys, other visceral organs, retroperitoneum, trunk, and extremities12,17,19,26,52. Exceedingly rare SMARCB1/INI1-deficient tumors that occur more commonly in adults include synovial sarcomas, epithelioid malignant peripheral nerve sheath tumor, myoepithelial carcinoma, extraskeletal myxoid chondrosarcoma, chordoma, schwannomatosis, gastrointestinal stromal tumors (GIST), and ossifying fibromyxoid tumor (Table 1). On light microscopy, these sarcomatous neoplasms exist on a morphological spectrum. Tissue specimens are often composed of epithelioid or rhabdoid cells53. However, other morphologic patterns have been described50. Thus, the diagnosis of SMARCB1/INI1-deficient tumors can be difficult based on their polyphenotypic variation4. SMARCB1/INI1 immunostaining can be used to confirm the diagnosis of an epithelioid or rhabdoid sarcoma because loss of SMARCB1/INI1 expression is rarely observed in other tumor types54,55. Thus, in the absence of this genetic alteration, other malignant soft tissue tumors with epithelioid-like morphologies can be more confidently ruled out, such as melanoma, rhabdomyosarcoma, and undifferentiated carcinoma.

Aside from SMARCB1/INI1-deficient tumors sharing an aberration in the same gene, the relationship between these malignancies remains unclear. Following diagnosis in any age or organ, nearly all SMARCB1/INI1-deficient malignancies characteristically follow an aggressive clinical pattern and prognosis is often poor (Table 1). Survival rates are often reportedly low, but they may not be accurate given low rates of incidence, and considerations for newer treatments. Also, survival can be highly dependent on surgical intervention and completeness of tumor resection, especially for chordomas. GIST are the most common sarcomas of the gastrointestinal (GI) tract. They commonly develop in the sixth decade of life and have no gender predominance35. Following the diagnosis of a GIST, survival rates are highly variable and depend on specific biologic characteristics of the tumor, the type of treatment, and the risk of post-treatment recurrence36.

Challenges in retrospective data collection for adult cases of SMARCB1/INI-deficient tumors

Recently, the term “rhabdoid tumor” has become synonymous with tumors that harbor loss of function mutations in the SMARCB1/INI1 gene56. We reviewed the literature and found a paucity of cases reporting SMARCB1/INI1 genetic aberrations in adult patients with sarcomas. A total of 450 cases of rare sarcomas were found to be described in single case reports, case series, or systematic reviews published between the years 2000 – 2020 (Table 2)5792. This number is likely far lower than the actual accounts of reported sarcoma cases in the literature. However, reports were excluded if it was apparent the case did not meet our inclusion criteria based on the publicly-available title or abstract information. Despite the SMARCB1/INI1 gene being discovered in the mid-1990s, the majority of previous reports were excluded for not mentioning the tumor’s SMARCB1/INI1-deficiency status. Also, tumor occurrence in the pediatric patient population accounted for multiple exclusions.

Table 2. Excluded rare sarcomas in adults reported in single case reports, case series, or systematic reviews, 2000–2020.

Exclusion criteria were as follows: 1.) individual patient age could not be confirmed; 2.) pediatric study population (less than 18 years of age); 3.) absence of documentation noting the loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; 4.) intact SMARCB1/INI1 expression by immunochemistry or genetic studies; and 5.) non-sarcomatous histologic tumor type. PMID, PubMed Central © unique article identifier; GU, genitourinary; PNS, peripheral nervous system; GI, gastrointestinal.

ArticlePMIDCases,
no.
Tumor
site
Exclusion
reason
ArticlePMIDCases,
no.
Tumor
site
Exclusion
reason
Zhang et al., 201957319337811scalp3Weisskopf et al., 200675164749441spine2,3
Kubota et al., 201958310347221GU2Onol et al., 200676163437341GU3
Kolin et al., 201859297004185GU4Zevallos-G. et al.,
200577
160822462perineum 3
Kim et al., 201860302357751brain3Masunaga et al.,
200478
152608531lung3
Strehl et al., 2015612592093925GU3Chang et al., 200479147138331GI2
Santos et al., 201362237932151pelvis3Altundag et al., 200480155799211GU3
Patrizi et al., 201363238864031GU3Lee et al., 200481146752881pelvis3
Zhao et al., 201349237610281renal3Peng et al., 200344129462141renal3
Tocco et al., 201264233598421scalp3Hanna et al., 200282121075738multiple 3
Rizzo et al., 2012652261400012PNS2Etienne-M. et al.,
200283
1244575012multiple 3,5
Kuge et al., 201266222187081brain2Moore et al., 200284119251501GU3
Hagström et al.,
201167
214206281oral 3Haidopoulos et al.,
200285
124408231GU3
Narendra et al.,
201068
204795531GU3Tzilinis et al., 200286160931951GU3
Tholpady et al.,
201069
208818481GU2Amrikachi et al., 200287124784864GI3
Chbani et al., 20095519141382106multiple 1Hasegawa et al., 2001881145499720multiple 3
Hornick et al.,
200970
19033866127multiple 1Kasamatsu et al.,
200189
115203721GU3
Kim et al., 200871194715671GU3Knapik et al., 200190115212351GU4
Rekhi et al., 2008721860762940multiple 3Biegal et al., 200091107383001brain2
Argenta et al.,
200773
176923651GU3Spillane et al., 2000921079185337multiple 3
Bourdeaut
et al., 200774
1715204926multiple2

We located 25 cases of adult SMARCB1/INI1-deficient sarcomas that were described in 18 reports (Table 3)42,50,93108. Median age at the time of diagnosis was 36 years old. A male predominance was mildly observed (14 cases, 56%), which is consistent with other larger reviews. Presentation in the head and neck (e.g. brain, eye, nose, and scalp) occurred more frequently (6 cases, 24%). No descriptive data analysis was performed to determine if our observations were significant. The majority of reports were originally described as proximal epithelioid sarcoma, but overall these remained a morphologically diverse group of cases that also included rhabdoid and mixed phenotypes.

Table 3. Included rare sarcomas reported in single case reports, case series, or systematic reviews, 2000–2020.

Inclusion criteria were as follows: ability to confirm an individual case patient was greater than 18 years of age; documentation of a loss of SMARCB1/INI1 expression by immunohistochemistry or genetic studies; and confirmed sarcomatous histologic tumor type. “ - “ denotes complete, reduced, or mosaic loss of SMARCB1/INI1 expression (exp.). M, male; F, female.

ArticlePMIDCases,
no.
Age,
Sex
Tumor
site
SMARCB1/
INI1 exp.
Sarcoma morphology
Parker et al., 20204232467817156 Minguinal-epithelioid, rhabdoid
Ahmad et al., 20199331737506127 Mpleura-epithelioid
Bodi et al., 20189429541486122 Fbrain-epithelioid, spindle-shaped
Gurwale et al., 201795-118 Fscalp-epithelioid
Saha D et al., 20169627045049141 Mlung-epithelioid
Rego et al., 20159725737787134 Fvulva-epithelioid, spindle-shaped
Wetzel et al., 20149824997629151 Foral-rhabdoid
Agaimy et al., 20149924503755166 Mstomach-rhabdoid
Madsen et al., 201310024457248145 Mpleura-epithelioid
Frank et al., 201310124308011143 Meye-epithelioid, spindle-shaped
271 Fnasal-epithelioid
Kim et al. 201210221724432141 Fvulva-epithelioid
Mannan et al., 201010319757197147 Minguinal-epithelioid
Takei et al., 201010419911885133 Fbrain-rhabdoid
279 Mcecum-rhabdoid
Raoux et al., 200910519342946131 Fbone-epithelioid, spindle-shaped
Robbens et al., 200610616602014119 Mvertebra-epithelioid
Sigauke et al., 200610716528370126 Mwrist-epithelioid
226 Mlymph -epithelioid
Perry et al., 200510815761491129 Msoft tissue-spindle-shaped
Modena et al., 20055015899790131 Fthigh-epithelioid
247 Fperineum-rhabdoid
330 Mspine-epithelioid
436 Mspine-epithelioid, spindle-shaped
566 Finguinal-epithelioid, rhabdoid

Treatment

Prior to, and still after, the discovery that SMARCB1/INI1-deficient tumors contribute to the large majority of soft tissue sarcomas, systemic cytotoxic agents have been used to treat this diverse group of neoplasms. Doxorubicin and ifosfamide have remained the mainstay of first-line treatment for advanced disease for the last few decades. Currently, the most widely used regimen for soft tissue sarcomas is termed AIM, which includes Adriamycin (doxorubicin) plus ifosfamide and mesna109111. Therapies such as these, and other cytotoxic agents, exhibit intermediate to improved anti-cancer activity, and prolong survival in metastatic soft tissue sarcoma (Table 4). However, refractory or progressive disease can occur. With the hopes of improving outcomes in patients who develop aggressive sarcomas, multiple new therapies are being introduced. Olaratumab, a monoclonal antibody that targets platelet-derived growth factor alpha and beta (PDGFRA/B), has been approved for first-line therapy in combination with doxorubicin due to improved progression and overall survival in sarcoma patients112. The use of tyrosine kinase-inhibitors (TKIs) has transformed the treatment of advanced GIST. Imatinib, a TKI, as monotherapy is now approved for upfront treatment of metastatic GIST due to improved side effect profiles and outcomes in these patients113115. Given its mechanism of action, imatinib is also approved for first-line treatment of the fibrosarcomatous variant of dermatofibrosarcoma protuberans116,117.

Table 4. Approved first-line treatments for sarcomas.

ORR, overall response rate; PFS, progression free survival; OS, overall survival; STS, soft tissue sarcoma; GIST, gastrointestinal stromal tumor; D, doxorubicine; I, ifosfamide; P, palifosfamide; E, Evofosfamide; T, trabectedin; O, Olaratumab; G, gemcitabine; Doc, docetaxel; NA, data not available.

TumorDrugsSchedulesORR
(%)
PFS
(months)
OS
(months)
Reference
STSDoxorubicin

Ifosfamide

Evofosfamide

Trabectedin

Olaratumab
D + I267.414.3128
D + P28.3615.9129
D + E28.46.318.4130
D + T175.713.3131
D + O18.26.626.5112
Trabectedinmonotherapy14.82.8NA132
Aldoxorubicinmonotherapy255.615.8133
Amrubicinmonotherapy135.826134
Gemcitabine

Docetaxel
G + Doc58.65.614.7135
Brostacillinmonotherapy3.91.6NA136
GISTImatinibmonotherapy68.11855113115
AngiosarcomaPaclitaxel monotherapyNA48137

Additional TKIs have recently been introduced, with clinical trial data showing promise for their use in sarcomas. Sunitinib and regorafenib significantly improve overall survival in imatinib-resistant GIST patients118. Pazopanib, a TKI that targets angiogenesis by inhibiting vascular endothelial growth factor receptor, PDGFRA/B, and KIT proto-oncogene, has been shown to improve progression free survival in certain histologic types of sarcoma. This led to its approval for advanced, refractory non-lipomatous sarcoma119,120. Alveolar sarcomas appear to respond well to anti-angiogenetic sorafenib and cediranib121,122. In phase II studies tivozanib, which mechanism of action mimics pazopanib, exhibits promising anti-cancer activity in metastatic or nonresectable soft tissue sarcomas123.

Recently, much work studying the complex mechanisms involved in sarcoma tumorigenesis has revealed the potential for numerous new drug targets. Targeting the mammalian target of rapamycin (mTOR) signaling pathway by serine/threonine kinase inhibition has been widely studied. However, thus far either only equivocal or minor benefits have been shown with the administration of these agents124. In contrast, phase II trial data is reassuring for the future use of palbociclib, a cyclin-dependent kinase 4 and 6 inhibitor approved in breast cancer, for liposarcoma125,126.

Preliminary data from pre-clinical and phase I/II trials is encouraging for small molecule inhibitors, such as with Murine double minute 2 (MDM2)–antagonists, histone deacetylase inhibitors, and histone methylation inhibitors124. A possible breakthrough in small molecular inhibition is represented by the recent discovery of a specific methyltransferase termed Enhancer of zeste homolog 2 (EZH2) is upregulated in SMARCB1/INI1-deficient tumors127. Given the defining characteristic of SMARCB1/INI1 deficiency in the nearly all soft tissue sarcomas, tazemetostat has emerged as an intriguing compound for its direct inhibition of histone-lysine N-methyltransferase EZH2127,138. Another new agent that hopes to improve outcomes for patients with these rare and aggressive SMARCB1/INI1-deficient rhabdoid sarcomas comes from the proteasome inhibitor drug class. Ixazomib selectively targets proteasomes involved in protein anabolism and cellular apoptosis, whose activity is directly enhanced by the transcription factor MYC in SMARCB1/INI1-deficient states. Currently, ixazomib plus gemcitabine and doxorubicin is being studied in the phase II trial setting for renal medullary carcinoma139,140.

Data availability

Underlying data

No data are associated with this article.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 30 Jun 2020
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Parker NA, Al-Obaidi A and Deutsch JM. SMARCB1/INI1-deficient tumors of adulthood [version 2; peer review: 2 approved]. F1000Research 2020, 9:662 (https://doi.org/10.12688/f1000research.24808.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 09 Dec 2020
Revised
Views
12
Cite
Reviewer Report 15 Mar 2021
Abdulqadir Nashwan, Research Scientist, Hamad Medical Corporation (HMC), Doha, Qatar 
Approved
VIEWS 12
This is a review article highlighting the recently published case reports on the role of SMARCB1/INI1-deficient tumors of adulthood and available treatment strategies.

This review summarized important findings and is theoretically based on the current literature.
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Nashwan A. Reviewer Report For: SMARCB1/INI1-deficient tumors of adulthood [version 2; peer review: 2 approved]. F1000Research 2020, 9:662 (https://doi.org/10.5256/f1000research.30897.r80638)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 30 Jun 2020
Views
22
Cite
Reviewer Report 05 Nov 2020
Conor Patrick Malone, Health Service Executive (Ireland), Dublin, Ireland 
Approved
VIEWS 22
This article clearly and concisely reviews the role of SMARCB1/INI1 in rhabdoid tumours, as well as summarising the literature and discussing management options. The structure is good, the language is accessible, and the references are appropriate and comprehensive.

I ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Malone CP. Reviewer Report For: SMARCB1/INI1-deficient tumors of adulthood [version 2; peer review: 2 approved]. F1000Research 2020, 9:662 (https://doi.org/10.5256/f1000research.27370.r74306)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 30 Jun 2020
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.